STOCK TITAN

[6-K] Jeffs' Brands Ltd Warrant Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

Jeffs’ Brands Ltd ("JFBR") has entered into a sizeable, highly flexible financing arrangement that could materially influence its capital structure and strategic options. On 26 June 2025 the company signed a Securities Purchase Agreement ("SPA") with an institutional investor allowing the issuance of up to $100 million in convertible promissory notes ("Notes"). An initial Note carrying $5 million principal was sold immediately for $4.5 million cash (10% original-issue discount). Beginning 1 December 2025, JFBR may request additional tranches of up to $2.5 million principal per quarter, likewise priced at 90% of face value. The company is not obligated to draw further funds and faces no minimum-use penalties.

Key terms of each Note include: (i) 4% annual interest (escalating to 14% upon default); (ii) repayment in ten equal monthly installments starting 18 months after issuance (Initial Note amortises from 26 Dec 2026); (iii) investor conversion option anytime at the lower of $6.80 or 88 % of the lowest 20-day VWAP, subject to a hard floor of $1.02856; and (iv) a 4.99 % beneficial-ownership cap. Aggregate issuance during the first five months is restricted to $50 million, then $25 million per subsequent quarter, and never above the $100 million ceiling.

The use of proceeds is earmarked for working capital, general corporate purposes and potential acquisitions as the company “explores strategic opportunities.” The SPA contains no operating covenants. As part of the transaction, JFBR paid Aegis Capital a $150 k advisory fee (3 % of the initial principal) and will pay the same 3 % on future Notes. The company has agreed to file a resale registration statement for shares issuable upon conversion, but the placement itself is exempt from U.S. registration.

Governance & related-party disclosure: CEO/director Mr. Vik Hacmon is related to the Holder’s controlling shareholder; the deal was therefore approved by the audit committee and board under Israeli Companies Law.

Investor considerations:

  • Provides rapid access to up to $100 million, enhancing liquidity for acquisitions or expansion.
  • Original-issue discount, conversion price set 12 % below market VWAP and registration of resale shares point to potential dilution and trading pressure.
  • Low initial coupon but step-up to 14 % on default raises downside risk if cash flows tighten.
  • No operating covenants give management latitude, but also leave investors without performance safeguards.

Jeffs’ Brands Ltd ("JFBR") ha stipulato un accordo di finanziamento consistente e altamente flessibile che potrebbe influenzare in modo significativo la sua struttura patrimoniale e le opzioni strategiche. Il 26 giugno 2025 la società ha firmato un Accordo di Acquisto di Titoli ("SPA") con un investitore istituzionale, consentendo l’emissione di note convertibili fino a 100 milioni di dollari. Una prima nota con un capitale di 5 milioni di dollari è stata venduta immediatamente per 4,5 milioni di dollari in contanti (sconto originale del 10%). A partire dal 1 dicembre 2025, JFBR potrà richiedere tranche aggiuntive fino a 2,5 milioni di dollari per trimestre, sempre a un prezzo pari al 90% del valore nominale. La società non è obbligata a utilizzare ulteriori fondi e non è soggetta a penali per mancato utilizzo.

I termini chiave di ogni nota includono: (i) interesse annuo del 4% (che aumenta al 14% in caso di inadempienza); (ii) rimborso in dieci rate mensili uguali a partire da 18 mesi dopo l’emissione (la nota iniziale si ammortizza dal 26 dicembre 2026); (iii) opzione di conversione per l’investitore in qualsiasi momento al prezzo più basso tra 6,80 dollari o il 88% del VWAP a 20 giorni più basso, con un limite minimo rigido di 1,02856 dollari; e (iv) un tetto di proprietà beneficiaria del 4,99%. L’emissione aggregata nei primi cinque mesi è limitata a 50 milioni di dollari, poi a 25 milioni di dollari per ogni trimestre successivo, senza mai superare il limite massimo di 100 milioni.

Il uso dei proventi è destinato al capitale circolante, a scopi aziendali generali e a potenziali acquisizioni, mentre la società "esplora opportunità strategiche". Lo SPA non prevede covenant operativi. Come parte della transazione, JFBR ha pagato ad Aegis Capital una commissione di consulenza di 150.000 dollari (3% del capitale iniziale) e pagherà la stessa percentuale del 3% sulle note future. La società si è impegnata a presentare una dichiarazione di registrazione per la rivendita delle azioni emesse in conversione, ma il collocamento stesso è esente dalla registrazione negli Stati Uniti.

Governance e dichiarazione di parti correlate: l’Amministratore Delegato e direttore, il Sig. Vik Hacmon, è legato al socio di controllo del detentore; pertanto, l’accordo è stato approvato dal comitato di revisione e dal consiglio secondo la legge israeliana sulle società.

Considerazioni per gli investitori:

  • Fornisce accesso rapido fino a 100 milioni di dollari, migliorando la liquidità per acquisizioni o espansioni.
  • Sconto all’emissione, prezzo di conversione fissato al 12% sotto il VWAP di mercato e registrazione delle azioni di rivendita indicano potenziale diluizione e pressione sul trading.
  • Coupon iniziale basso ma aumento al 14% in caso di inadempienza aumenta il rischio in caso di flussi di cassa ridotti.
  • Assenza di covenant operativi offre flessibilità al management, ma lascia gli investitori senza garanzie di performance.

Jeffs’ Brands Ltd ("JFBR") ha establecido un acuerdo de financiamiento considerable y altamente flexible que podría influir significativamente en su estructura de capital y opciones estratégicas. El 26 de junio de 2025, la empresa firmó un Acuerdo de Compra de Valores ("SPA") con un inversor institucional que permite la emisión de pagarés convertibles hasta por 100 millones de dólares. Se vendió inmediatamente un pagaré inicial con un principal de 5 millones de dólares por 4.5 millones de dólares en efectivo (descuento original del 10%). A partir del 1 de diciembre de 2025, JFBR podrá solicitar tramos adicionales de hasta 2.5 millones de dólares por trimestre, también valorados al 90% del valor nominal. La compañía no está obligada a tomar fondos adicionales y no enfrenta penalizaciones por no utilizarlos.

Los términos clave de cada pagaré incluyen: (i) interés anual del 4% (que aumenta al 14% en caso de incumplimiento); (ii) reembolso en diez cuotas mensuales iguales comenzando 18 meses después de la emisión (el pagaré inicial se amortiza desde el 26 de diciembre de 2026); (iii) opción de conversión para el inversor en cualquier momento al menor valor entre 6.80 dólares o el 88% del VWAP más bajo de 20 días, sujeto a un límite mínimo estricto de 1.02856 dólares; y (iv) un tope de propiedad beneficiaria del 4,99%. La emisión agregada durante los primeros cinco meses está limitada a 50 millones de dólares, luego a 25 millones de dólares por trimestre posterior, y nunca excede el techo de 100 millones.

El uso de los fondos está destinado a capital de trabajo, propósitos corporativos generales y posibles adquisiciones, mientras la empresa "explora oportunidades estratégicas". El SPA no contiene convenios operativos. Como parte de la transacción, JFBR pagó a Aegis Capital una tarifa de asesoría de 150,000 dólares (3% del principal inicial) y pagará el mismo 3% en futuros pagarés. La empresa acordó presentar una declaración de registro para la reventa de acciones emitidas en conversión, pero la colocación está exenta de registro en EE.UU.

Gobernanza y divulgación de partes relacionadas: El CEO/director, Sr. Vik Hacmon, está relacionado con el accionista controlador del titular; por lo tanto, el acuerdo fue aprobado por el comité de auditoría y la junta según la Ley de Sociedades israelí.

Consideraciones para inversores:

  • Proporciona acceso rápido hasta 100 millones de dólares, mejorando la liquidez para adquisiciones o expansión.
  • Descuento original, precio de conversión fijado un 12% por debajo del VWAP de mercado y registro de acciones para reventa apuntan a posible dilución y presión en el mercado.
  • Bajo cupón inicial pero aumento al 14% en caso de incumplimiento incrementa el riesgo si los flujos de caja se ajustan.
  • Ausencia de convenios operativos da flexibilidad a la gestión, pero deja a los inversores sin garantías de desempeño.

Jeffs’ Brands Ltd("JFBR")는 자본 구조와 전략적 선택에 중대한 영향을 미칠 수 있는 대규모이면서도 매우 유연한 자금 조달 계약을 체결했습니다. 2025년 6월 26일, 회사는 기관 투자자와 증권 매매 계약("SPA")을 체결하여 최대 1억 달러의 전환 사채("Notes") 발행을 허용했습니다. 초기 사채 1건은 원금 500만 달러로 즉시 450만 달러 현금(10% 최초 발행 할인)로 판매되었습니다. 2025년 12월 1일부터 JFBR는 분기별로 최대 250만 달러 원금의 추가 트랜치를 요청할 수 있으며, 이 역시 액면가의 90%로 가격이 책정됩니다. 회사는 추가 자금 인출 의무가 없으며 최소 사용 페널티도 없습니다.

각 사채의 주요 조건은 다음과 같습니다: (i) 연 4% 이자(채무 불이행 시 14%로 상승); (ii) 발행 후 18개월부터 10회 동일 월별 분할 상환(초기 사채는 2026년 12월 26일부터 상환 시작); (iii) 투자자는 언제든지 6.80달러 또는 최저 20일 VWAP의 88% 중 낮은 가격으로 전환 가능하며, 최저 가격은 1.02856달러로 제한됨; (iv) 4.99%의 실질 소유 한도. 첫 5개월간 총 발행 한도는 5천만 달러, 이후 분기별 2천5백만 달러로 제한되며, 총 한도는 1억 달러를 초과하지 않습니다.

자금 사용 목적은 운전자본, 일반 기업 목적 및 잠재적 인수에 할당되며, 회사는 "전략적 기회 탐색"을 진행 중입니다. SPA에는 운영 관련 계약 조항이 없습니다. 거래의 일환으로 JFBR는 Aegis Capital에 15만 달러의 자문 수수료(초기 원금의 3%)를 지급했으며, 향후 사채에도 동일한 3% 수수료를 지급할 예정입니다. 회사는 전환 시 발행되는 주식에 대해 재판매 등록 명세서를 제출하기로 합의했으나, 이번 배치는 미국 등록 면제 대상입니다.

거버넌스 및 특수관계인 공시: CEO 겸 이사인 Vik Hacmon 씨는 보유자의 최대 주주와 관련이 있으므로, 본 거래는 이스라엘 회사법에 따라 감사위원회와 이사회의 승인을 받았습니다.

투자자 고려사항:

  • 최대 1억 달러까지 신속한 자금 조달로 인수 또는 확장에 대한 유동성 강화.
  • 초기 발행 할인, 시장 VWAP보다 12% 낮은 전환 가격, 재판매 주식 등록은 잠재적 희석 및 거래 압력 시사.
  • 초기 낮은 쿠폰이지만 채무 불이행 시 14%로 상승하여 현금 흐름 악화 시 하방 위험 증가.
  • 운영 관련 계약 조항 부재로 경영진에 유연성을 제공하지만 투자자에게는 성과 보호 장치 부재.

Jeffs’ Brands Ltd ("JFBR") a conclu un accord de financement important et très flexible qui pourrait influencer de manière significative sa structure de capital et ses options stratégiques. Le 26 juin 2025, la société a signé un accord d'achat de titres ("SPA") avec un investisseur institutionnel autorisant l'émission de billets convertibles jusqu'à 100 millions de dollars. Un billet initial d'un principal de 5 millions de dollars a été vendu immédiatement pour 4,5 millions de dollars en espèces (escompte initial de 10%). À partir du 1er décembre 2025, JFBR pourra demander des tranches supplémentaires jusqu'à 2,5 millions de dollars par trimestre, également valorisées à 90% de la valeur nominale. La société n'est pas obligée de lever des fonds supplémentaires et n'encourt aucune pénalité en cas de non-utilisation.

Les conditions clés de chaque billet incluent : (i) un intérêt annuel de 4% (pouvant passer à 14% en cas de défaut) ; (ii) remboursement en dix versements mensuels égaux commençant 18 mois après l'émission (le billet initial s'amortit à partir du 26 décembre 2026) ; (iii) option de conversion pour l'investisseur à tout moment au plus bas entre 6,80 dollars ou 88 % du VWAP sur 20 jours le plus bas, avec un plancher strict de 1,02856 dollar ; et (iv) un plafond de détention bénéficiaire de 4,99 %. L'émission totale au cours des cinq premiers mois est limitée à 50 millions de dollars, puis à 25 millions de dollars par trimestre suivant, sans jamais dépasser le plafond de 100 millions.

L'utilisation des fonds est destinée au fonds de roulement, aux besoins généraux de l'entreprise et à d'éventuelles acquisitions, alors que la société « explore des opportunités stratégiques ». Le SPA ne contient pas de clauses opérationnelles. Dans le cadre de la transaction, JFBR a versé à Aegis Capital des frais de conseil de 150 000 dollars (3 % du principal initial) et versera le même 3 % sur les futurs billets. La société s'est engagée à déposer une déclaration d'enregistrement pour la revente des actions émises lors de la conversion, mais le placement lui-même est exempt d'enregistrement aux États-Unis.

Gouvernance et divulgation des parties liées : Le PDG/directeur, M. Vik Hacmon, est lié à l'actionnaire contrôlant du détenteur ; l'accord a donc été approuvé par le comité d'audit et le conseil d'administration conformément à la loi israélienne sur les sociétés.

Considérations pour les investisseurs :

  • Offre un accès rapide jusqu'à 100 millions de dollars, améliorant la liquidité pour les acquisitions ou l'expansion.
  • Escompte initial, prix de conversion fixé 12 % sous le VWAP du marché et enregistrement des actions de revente indiquent un potentiel de dilution et une pression sur les cours.
  • Coupon initial faible mais augmentation à 14 % en cas de défaut, ce qui accroît le risque en cas de resserrement des flux de trésorerie.
  • Absence de clauses opérationnelles offrant une latitude à la direction, mais laissant les investisseurs sans garanties de performance.

Jeffs’ Brands Ltd ("JFBR") hat eine umfangreiche, hochflexible Finanzierungsvereinbarung abgeschlossen, die seine Kapitalstruktur und strategischen Optionen maßgeblich beeinflussen könnte. Am 26. Juni 2025 unterzeichnete das Unternehmen eine Wertpapierkaufvereinbarung ("SPA") mit einem institutionellen Investor, die die Ausgabe von bis zu 100 Millionen US-Dollar an wandelbaren Schuldscheinen ("Notes") ermöglicht. Eine erste Note mit einem Nennwert von 5 Millionen US-Dollar wurde sofort für 4,5 Millionen US-Dollar in bar verkauft (10% Emissionsabschlag). Ab dem 1. Dezember 2025 kann JFBR vierteljährlich zusätzliche Tranchen von bis zu 2,5 Millionen US-Dollar Nennwert anfordern, ebenfalls zum Preis von 90% des Nennwerts. Das Unternehmen ist nicht verpflichtet, weitere Mittel abzurufen, und es gibt keine Mindestnutzungsstrafen.

Wesentliche Bedingungen jeder Note umfassen: (i) 4% Jahreszins (steigend auf 14% bei Zahlungsverzug); (ii) Rückzahlung in zehn gleichen monatlichen Raten beginnend 18 Monate nach Ausgabe (die Anfangsnote amortisiert ab dem 26. Dezember 2026); (iii) Investoren haben jederzeit eine Wandlungsoption zum niedrigeren Wert von 6,80 US-Dollar oder 88 % des niedrigsten 20-Tage VWAP, mit einem harten Mindestpreis von 1,02856 US-Dollar; und (iv) eine Besitzanteilsobergrenze von 4,99%. Die Gesamtemission in den ersten fünf Monaten ist auf 50 Millionen US-Dollar begrenzt, danach auf 25 Millionen US-Dollar pro Quartal, jedoch niemals über der Obergrenze von 100 Millionen.

Die Verwendung der Erlöse ist für Betriebskapital, allgemeine Unternehmenszwecke und potenzielle Akquisitionen vorgesehen, während das Unternehmen "strategische Möglichkeiten erkundet." Das SPA enthält keine operativen Auflagen. Im Rahmen der Transaktion zahlte JFBR Aegis Capital eine Beratungsgebühr von 150.000 US-Dollar (3 % des Anfangskapitals) und wird auch bei zukünftigen Notes 3 % zahlen. Das Unternehmen hat sich verpflichtet, eine Registrierungserklärung für den Wiederverkauf der bei Wandlung auszugebenden Aktien einzureichen, aber die Platzierung selbst ist von der US-Registrierung ausgenommen.

Governance & Offenlegung von verbundenen Parteien: CEO und Direktor Herr Vik Hacmon steht in Beziehung zum Mehrheitsaktionär des Inhabers; daher wurde der Deal vom Prüfungsausschuss und Vorstand gemäß dem israelischen Gesellschaftsrecht genehmigt.

Überlegungen für Investoren:

  • Bietet schnellen Zugang zu bis zu 100 Millionen US-Dollar, verbessert die Liquidität für Akquisitionen oder Expansion.
  • Emissionsabschlag, Wandlungspreis 12 % unter dem Markt-VWAP und Registrierung der Wiederverkaufsaktien deuten auf potenzielle Verwässerung und Handelsdruck hin.
  • Niedriger Anfangszins, aber Anstieg auf 14 % bei Zahlungsverzug erhöht das Abwärtsrisiko bei engen Cashflows.
  • Keine operativen Auflagen geben dem Management Spielraum, lassen Investoren aber ohne Leistungsschutz.
Positive
  • Access to up to $100 million in convertible financing enhances liquidity for growth and acquisitions without mandatory drawdown obligations.
  • Low 4 % coupon and 18-month repayment grace period limit immediate cash outflow.
  • No operating covenants or minimum-use penalties preserve management flexibility.
Negative
  • 10 % original-issue discount and 12 % conversion discount create significant potential dilution and stock overhang.
  • Conversion floor of $1.02856 is well below recent prices, increasing downside dilution risk if shares decline.
  • Interest rate escalates to 14 % on default, adding financial risk in adverse scenarios.
  • Related-party connection between CEO and Holder could raise conflict-of-interest concerns despite board approval.

Insights

TL;DR: Flexible $100 m convert boosts liquidity but embeds meaningful dilution and discount risk.

The SPA offers JFBR an opportunistic war-chest as it hunts acquisitions. The 4 % coupon and 18-month repayment deferral reduce near-term cash burn, while the absence of mandatory draws preserves optionality. However, the 10 % OID plus 12 % conversion discount renders the structure economically expensive and share-price dilutive. A hard floor of $1.02856 limits extreme downside, yet still sits far below recent trading, inviting conversion activity should the equity weaken. The 4.99 % cap tempers, but does not eliminate, sell-pressure because the Holder can recycle its position once shares are sold. Net impact is moderately positive for liquidity but neutral for value due to dilution.

TL;DR: Related-party aspect handled procedurally, but dilution mechanics raise governance optics.

Management disclosed the CEO’s familial link to the Holder and obtained audit-committee and board approval, aligning with Israeli Companies Law. Still, investors may question whether alternative, less dilutive financing was considered. The registration requirement suggests imminent resale, heightening overhang concerns. From a governance standpoint, transparency is adequate, yet structure remains shareholder-unfriendly due to potential value transfer via discounts and advisory fees.

Jeffs’ Brands Ltd ("JFBR") ha stipulato un accordo di finanziamento consistente e altamente flessibile che potrebbe influenzare in modo significativo la sua struttura patrimoniale e le opzioni strategiche. Il 26 giugno 2025 la società ha firmato un Accordo di Acquisto di Titoli ("SPA") con un investitore istituzionale, consentendo l’emissione di note convertibili fino a 100 milioni di dollari. Una prima nota con un capitale di 5 milioni di dollari è stata venduta immediatamente per 4,5 milioni di dollari in contanti (sconto originale del 10%). A partire dal 1 dicembre 2025, JFBR potrà richiedere tranche aggiuntive fino a 2,5 milioni di dollari per trimestre, sempre a un prezzo pari al 90% del valore nominale. La società non è obbligata a utilizzare ulteriori fondi e non è soggetta a penali per mancato utilizzo.

I termini chiave di ogni nota includono: (i) interesse annuo del 4% (che aumenta al 14% in caso di inadempienza); (ii) rimborso in dieci rate mensili uguali a partire da 18 mesi dopo l’emissione (la nota iniziale si ammortizza dal 26 dicembre 2026); (iii) opzione di conversione per l’investitore in qualsiasi momento al prezzo più basso tra 6,80 dollari o il 88% del VWAP a 20 giorni più basso, con un limite minimo rigido di 1,02856 dollari; e (iv) un tetto di proprietà beneficiaria del 4,99%. L’emissione aggregata nei primi cinque mesi è limitata a 50 milioni di dollari, poi a 25 milioni di dollari per ogni trimestre successivo, senza mai superare il limite massimo di 100 milioni.

Il uso dei proventi è destinato al capitale circolante, a scopi aziendali generali e a potenziali acquisizioni, mentre la società "esplora opportunità strategiche". Lo SPA non prevede covenant operativi. Come parte della transazione, JFBR ha pagato ad Aegis Capital una commissione di consulenza di 150.000 dollari (3% del capitale iniziale) e pagherà la stessa percentuale del 3% sulle note future. La società si è impegnata a presentare una dichiarazione di registrazione per la rivendita delle azioni emesse in conversione, ma il collocamento stesso è esente dalla registrazione negli Stati Uniti.

Governance e dichiarazione di parti correlate: l’Amministratore Delegato e direttore, il Sig. Vik Hacmon, è legato al socio di controllo del detentore; pertanto, l’accordo è stato approvato dal comitato di revisione e dal consiglio secondo la legge israeliana sulle società.

Considerazioni per gli investitori:

  • Fornisce accesso rapido fino a 100 milioni di dollari, migliorando la liquidità per acquisizioni o espansioni.
  • Sconto all’emissione, prezzo di conversione fissato al 12% sotto il VWAP di mercato e registrazione delle azioni di rivendita indicano potenziale diluizione e pressione sul trading.
  • Coupon iniziale basso ma aumento al 14% in caso di inadempienza aumenta il rischio in caso di flussi di cassa ridotti.
  • Assenza di covenant operativi offre flessibilità al management, ma lascia gli investitori senza garanzie di performance.

Jeffs’ Brands Ltd ("JFBR") ha establecido un acuerdo de financiamiento considerable y altamente flexible que podría influir significativamente en su estructura de capital y opciones estratégicas. El 26 de junio de 2025, la empresa firmó un Acuerdo de Compra de Valores ("SPA") con un inversor institucional que permite la emisión de pagarés convertibles hasta por 100 millones de dólares. Se vendió inmediatamente un pagaré inicial con un principal de 5 millones de dólares por 4.5 millones de dólares en efectivo (descuento original del 10%). A partir del 1 de diciembre de 2025, JFBR podrá solicitar tramos adicionales de hasta 2.5 millones de dólares por trimestre, también valorados al 90% del valor nominal. La compañía no está obligada a tomar fondos adicionales y no enfrenta penalizaciones por no utilizarlos.

Los términos clave de cada pagaré incluyen: (i) interés anual del 4% (que aumenta al 14% en caso de incumplimiento); (ii) reembolso en diez cuotas mensuales iguales comenzando 18 meses después de la emisión (el pagaré inicial se amortiza desde el 26 de diciembre de 2026); (iii) opción de conversión para el inversor en cualquier momento al menor valor entre 6.80 dólares o el 88% del VWAP más bajo de 20 días, sujeto a un límite mínimo estricto de 1.02856 dólares; y (iv) un tope de propiedad beneficiaria del 4,99%. La emisión agregada durante los primeros cinco meses está limitada a 50 millones de dólares, luego a 25 millones de dólares por trimestre posterior, y nunca excede el techo de 100 millones.

El uso de los fondos está destinado a capital de trabajo, propósitos corporativos generales y posibles adquisiciones, mientras la empresa "explora oportunidades estratégicas". El SPA no contiene convenios operativos. Como parte de la transacción, JFBR pagó a Aegis Capital una tarifa de asesoría de 150,000 dólares (3% del principal inicial) y pagará el mismo 3% en futuros pagarés. La empresa acordó presentar una declaración de registro para la reventa de acciones emitidas en conversión, pero la colocación está exenta de registro en EE.UU.

Gobernanza y divulgación de partes relacionadas: El CEO/director, Sr. Vik Hacmon, está relacionado con el accionista controlador del titular; por lo tanto, el acuerdo fue aprobado por el comité de auditoría y la junta según la Ley de Sociedades israelí.

Consideraciones para inversores:

  • Proporciona acceso rápido hasta 100 millones de dólares, mejorando la liquidez para adquisiciones o expansión.
  • Descuento original, precio de conversión fijado un 12% por debajo del VWAP de mercado y registro de acciones para reventa apuntan a posible dilución y presión en el mercado.
  • Bajo cupón inicial pero aumento al 14% en caso de incumplimiento incrementa el riesgo si los flujos de caja se ajustan.
  • Ausencia de convenios operativos da flexibilidad a la gestión, pero deja a los inversores sin garantías de desempeño.

Jeffs’ Brands Ltd("JFBR")는 자본 구조와 전략적 선택에 중대한 영향을 미칠 수 있는 대규모이면서도 매우 유연한 자금 조달 계약을 체결했습니다. 2025년 6월 26일, 회사는 기관 투자자와 증권 매매 계약("SPA")을 체결하여 최대 1억 달러의 전환 사채("Notes") 발행을 허용했습니다. 초기 사채 1건은 원금 500만 달러로 즉시 450만 달러 현금(10% 최초 발행 할인)로 판매되었습니다. 2025년 12월 1일부터 JFBR는 분기별로 최대 250만 달러 원금의 추가 트랜치를 요청할 수 있으며, 이 역시 액면가의 90%로 가격이 책정됩니다. 회사는 추가 자금 인출 의무가 없으며 최소 사용 페널티도 없습니다.

각 사채의 주요 조건은 다음과 같습니다: (i) 연 4% 이자(채무 불이행 시 14%로 상승); (ii) 발행 후 18개월부터 10회 동일 월별 분할 상환(초기 사채는 2026년 12월 26일부터 상환 시작); (iii) 투자자는 언제든지 6.80달러 또는 최저 20일 VWAP의 88% 중 낮은 가격으로 전환 가능하며, 최저 가격은 1.02856달러로 제한됨; (iv) 4.99%의 실질 소유 한도. 첫 5개월간 총 발행 한도는 5천만 달러, 이후 분기별 2천5백만 달러로 제한되며, 총 한도는 1억 달러를 초과하지 않습니다.

자금 사용 목적은 운전자본, 일반 기업 목적 및 잠재적 인수에 할당되며, 회사는 "전략적 기회 탐색"을 진행 중입니다. SPA에는 운영 관련 계약 조항이 없습니다. 거래의 일환으로 JFBR는 Aegis Capital에 15만 달러의 자문 수수료(초기 원금의 3%)를 지급했으며, 향후 사채에도 동일한 3% 수수료를 지급할 예정입니다. 회사는 전환 시 발행되는 주식에 대해 재판매 등록 명세서를 제출하기로 합의했으나, 이번 배치는 미국 등록 면제 대상입니다.

거버넌스 및 특수관계인 공시: CEO 겸 이사인 Vik Hacmon 씨는 보유자의 최대 주주와 관련이 있으므로, 본 거래는 이스라엘 회사법에 따라 감사위원회와 이사회의 승인을 받았습니다.

투자자 고려사항:

  • 최대 1억 달러까지 신속한 자금 조달로 인수 또는 확장에 대한 유동성 강화.
  • 초기 발행 할인, 시장 VWAP보다 12% 낮은 전환 가격, 재판매 주식 등록은 잠재적 희석 및 거래 압력 시사.
  • 초기 낮은 쿠폰이지만 채무 불이행 시 14%로 상승하여 현금 흐름 악화 시 하방 위험 증가.
  • 운영 관련 계약 조항 부재로 경영진에 유연성을 제공하지만 투자자에게는 성과 보호 장치 부재.

Jeffs’ Brands Ltd ("JFBR") a conclu un accord de financement important et très flexible qui pourrait influencer de manière significative sa structure de capital et ses options stratégiques. Le 26 juin 2025, la société a signé un accord d'achat de titres ("SPA") avec un investisseur institutionnel autorisant l'émission de billets convertibles jusqu'à 100 millions de dollars. Un billet initial d'un principal de 5 millions de dollars a été vendu immédiatement pour 4,5 millions de dollars en espèces (escompte initial de 10%). À partir du 1er décembre 2025, JFBR pourra demander des tranches supplémentaires jusqu'à 2,5 millions de dollars par trimestre, également valorisées à 90% de la valeur nominale. La société n'est pas obligée de lever des fonds supplémentaires et n'encourt aucune pénalité en cas de non-utilisation.

Les conditions clés de chaque billet incluent : (i) un intérêt annuel de 4% (pouvant passer à 14% en cas de défaut) ; (ii) remboursement en dix versements mensuels égaux commençant 18 mois après l'émission (le billet initial s'amortit à partir du 26 décembre 2026) ; (iii) option de conversion pour l'investisseur à tout moment au plus bas entre 6,80 dollars ou 88 % du VWAP sur 20 jours le plus bas, avec un plancher strict de 1,02856 dollar ; et (iv) un plafond de détention bénéficiaire de 4,99 %. L'émission totale au cours des cinq premiers mois est limitée à 50 millions de dollars, puis à 25 millions de dollars par trimestre suivant, sans jamais dépasser le plafond de 100 millions.

L'utilisation des fonds est destinée au fonds de roulement, aux besoins généraux de l'entreprise et à d'éventuelles acquisitions, alors que la société « explore des opportunités stratégiques ». Le SPA ne contient pas de clauses opérationnelles. Dans le cadre de la transaction, JFBR a versé à Aegis Capital des frais de conseil de 150 000 dollars (3 % du principal initial) et versera le même 3 % sur les futurs billets. La société s'est engagée à déposer une déclaration d'enregistrement pour la revente des actions émises lors de la conversion, mais le placement lui-même est exempt d'enregistrement aux États-Unis.

Gouvernance et divulgation des parties liées : Le PDG/directeur, M. Vik Hacmon, est lié à l'actionnaire contrôlant du détenteur ; l'accord a donc été approuvé par le comité d'audit et le conseil d'administration conformément à la loi israélienne sur les sociétés.

Considérations pour les investisseurs :

  • Offre un accès rapide jusqu'à 100 millions de dollars, améliorant la liquidité pour les acquisitions ou l'expansion.
  • Escompte initial, prix de conversion fixé 12 % sous le VWAP du marché et enregistrement des actions de revente indiquent un potentiel de dilution et une pression sur les cours.
  • Coupon initial faible mais augmentation à 14 % en cas de défaut, ce qui accroît le risque en cas de resserrement des flux de trésorerie.
  • Absence de clauses opérationnelles offrant une latitude à la direction, mais laissant les investisseurs sans garanties de performance.

Jeffs’ Brands Ltd ("JFBR") hat eine umfangreiche, hochflexible Finanzierungsvereinbarung abgeschlossen, die seine Kapitalstruktur und strategischen Optionen maßgeblich beeinflussen könnte. Am 26. Juni 2025 unterzeichnete das Unternehmen eine Wertpapierkaufvereinbarung ("SPA") mit einem institutionellen Investor, die die Ausgabe von bis zu 100 Millionen US-Dollar an wandelbaren Schuldscheinen ("Notes") ermöglicht. Eine erste Note mit einem Nennwert von 5 Millionen US-Dollar wurde sofort für 4,5 Millionen US-Dollar in bar verkauft (10% Emissionsabschlag). Ab dem 1. Dezember 2025 kann JFBR vierteljährlich zusätzliche Tranchen von bis zu 2,5 Millionen US-Dollar Nennwert anfordern, ebenfalls zum Preis von 90% des Nennwerts. Das Unternehmen ist nicht verpflichtet, weitere Mittel abzurufen, und es gibt keine Mindestnutzungsstrafen.

Wesentliche Bedingungen jeder Note umfassen: (i) 4% Jahreszins (steigend auf 14% bei Zahlungsverzug); (ii) Rückzahlung in zehn gleichen monatlichen Raten beginnend 18 Monate nach Ausgabe (die Anfangsnote amortisiert ab dem 26. Dezember 2026); (iii) Investoren haben jederzeit eine Wandlungsoption zum niedrigeren Wert von 6,80 US-Dollar oder 88 % des niedrigsten 20-Tage VWAP, mit einem harten Mindestpreis von 1,02856 US-Dollar; und (iv) eine Besitzanteilsobergrenze von 4,99%. Die Gesamtemission in den ersten fünf Monaten ist auf 50 Millionen US-Dollar begrenzt, danach auf 25 Millionen US-Dollar pro Quartal, jedoch niemals über der Obergrenze von 100 Millionen.

Die Verwendung der Erlöse ist für Betriebskapital, allgemeine Unternehmenszwecke und potenzielle Akquisitionen vorgesehen, während das Unternehmen "strategische Möglichkeiten erkundet." Das SPA enthält keine operativen Auflagen. Im Rahmen der Transaktion zahlte JFBR Aegis Capital eine Beratungsgebühr von 150.000 US-Dollar (3 % des Anfangskapitals) und wird auch bei zukünftigen Notes 3 % zahlen. Das Unternehmen hat sich verpflichtet, eine Registrierungserklärung für den Wiederverkauf der bei Wandlung auszugebenden Aktien einzureichen, aber die Platzierung selbst ist von der US-Registrierung ausgenommen.

Governance & Offenlegung von verbundenen Parteien: CEO und Direktor Herr Vik Hacmon steht in Beziehung zum Mehrheitsaktionär des Inhabers; daher wurde der Deal vom Prüfungsausschuss und Vorstand gemäß dem israelischen Gesellschaftsrecht genehmigt.

Überlegungen für Investoren:

  • Bietet schnellen Zugang zu bis zu 100 Millionen US-Dollar, verbessert die Liquidität für Akquisitionen oder Expansion.
  • Emissionsabschlag, Wandlungspreis 12 % unter dem Markt-VWAP und Registrierung der Wiederverkaufsaktien deuten auf potenzielle Verwässerung und Handelsdruck hin.
  • Niedriger Anfangszins, aber Anstieg auf 14 % bei Zahlungsverzug erhöht das Abwärtsrisiko bei engen Cashflows.
  • Keine operativen Auflagen geben dem Management Spielraum, lassen Investoren aber ohne Leistungsschutz.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

Report of Foreign Private Issuer

 

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of June 2025

 

Commission File Number: 001-41482

 

JEFFS’ BRANDS LTD

(Translation of registrant’s name into English)

 

7 Mezada St.

Bnei Brak, Israel 5126112

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F   Form 40-F  

 

 

 

 

CONTENTS

 

Convertible Promissory Note

 

On June 26, 2025, Jeffs’ Brands Ltd (the “Company” or “Jeffs’ Brands”) entered into a Securities Purchase Agreement (the “SPA”), with an institutional investor (the “Holder”). Pursuant to the SPA, the Company may issue and sell, from time to time, convertible promissory notes (the “Notes”), in the aggregate principal amount of up to $100,000,000 (the “Subscription Amount”). Upon the signing of the SPA, on June 26, 2025 (the “Initial Closing”), the Holder purchased from the Company a Note in the principal amount of $5,000,000 for a purchase price of $4,500,000 (the “Initial Note”). Subject to the conditions in the SPA, beginning on December 1, 2025, the Company may request, at its sole discretion, that the Holder purchase additional Notes, each in the principal amount of up to $2,500,000, with a purchase price payable in cash and equal to 90% of such principal amount, during each subsequent three-month period. The Company intends to use the net proceeds from the sale of the Notes for working capital and general corporate purposes, as well as for potential acquisitions to support its exploration of strategic opportunities.

 

Notwithstanding the foregoing, if at any time after the Initial Closing, the daily trading volume of the Company’s ordinary shares, no par value (the “Ordinary Shares”), is at least 150% of the amount of Ordinary Shares then outstanding, then the Company may request, at its sole discretion, that the Holder purchase additional Notes for a purchase price payable in cash equal to 90% of the principal amount, provided however that the aggregate principal amount of Notes purchased pursuant to the SPA shall not exceed $50,000,000 during the period commencing as of the Initial Closing and until December 1, 2025, and thereafter shall not exceed $25,000,000 during each subsequent three-month period, and provided further that the aggregate principal amount of all Notes purchased pursuant to the SPA shall not exceed the Subscription Amount. 

 

Each Note will be issued at a purchase price equal to 90% of the principal amount of such Note, and is to be repaid, together with the accrued due interest, in ten equal monthly installments beginning on the eighteenth month anniversary of its issuance date, unless repaid earlier (partially or in full) at the option of the Company or if extended at the option of the Holder. The principal amount under each Note will bear an annual interest rate of 4% (which will increase to 14% upon an Event of Default, as defined in the Note). Thus, Initial Note is to be repaid in ten equal monthly installments commencing on December 26, 2026. The outstanding amount due under each Note is convertible into Ordinary Shares at the option of the Holder, at any time after the issuance date of such Note, at a conversion price equal to the lower of (i) $6.80 and (ii) 88% of the lowest daily volume weighted average price during the 20 consecutive trading days immediately preceding the applicable date of conversion (the “Variable Price”), provided that such Variable Price may not be lower than the floor price of $1.02856 per Ordinary Share, which is equal to 20% of the VWAP of the Ordinary Shares during the 20 consecutive trading days immediately prior to the Initial Closing, subject to certain adjustments as provided in the Note. The Holder’s option to convert the outstanding amount due is subject to the limitation that the conversion may not result in the Holder’s beneficial ownership exceeding 4.99% of the outstanding Ordinary Shares.

 

The Company is not obligated to utilize any of the remaining Subscription Amount available under the SPA, which as of the date hereof is $95,000,000, and there are no minimum commitments or minimum use penalties. The SPA does not impose any restrictions on the Company’s operating activities.

 

The SPA contains customary representations, warranties and representations by the Company. The descriptions of the SPA and Form of Note set forth above are qualified in their entirety by reference to the full text of those documents, which are attached hereto as Exhibits 10.1 and 4.1, respectively. 

 

Mr. Vik Hacmon, the Company’s chief executive officer and director, may be deemed to have a personal interest in the transaction by virtue of him being a relative of the controlling shareholder of the Holder, and as such the transaction was approved by the Company’s audit committee and board of directors in accordance with the Israeli Companies Law-1999.

 

The securities described above (the “Securities”) were and will be issued and sold in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the “Act”), and have not been registered under the Act, or applicable state securities laws. Accordingly, the Securities may not be sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities law. The Company has agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) to register the resale of the Ordinary Shares issuable upon conversion of the Notes. 

 

1

 

This Report of Foreign Private Issuer on Form 6-K shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

 

Advisory Agreement

 

In connection with the execution of the SPA, on June 26, 2025, the Company entered into a Strategic Advisory Agreement (the “Advisory Agreement”) with Aegis Capital Corp. (“Aegis”), pursuant to which Aegis provided the Company with independent advisory services related to the transactions contemplated under the SPA. In consideration of the advisory services, upon the issuance of the Initial Note, the Company paid Aegis a commission fee of $150,000, which is equal to 3% of the principal amount of the Initial Note issued and shall pay Aegis a commission fee for each additional Note issued equal to 3% of the principal amount of such additional Note. The Advisory Agreement will terminate on June 26, 2026, unless terminated earlier by either party. 

 

The Advisory Agreement contains customary warranties and agreements by the Company. The description of the Advisory Agreement set forth above is qualified in its entirety by reference to the full text of the Advisory Agreement, which is attached hereto as Exhibit 10.2.

 

Press Release

 

On June 26, 2025, the Company issued a press release titled “Jeffs’ Brands Secures $100 million Securities Purchase Agreement to support the Exploration of Strategic Opportunities,” a copy of which is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K.

 

This Report of Foreign Private Issuer on Form 6-K, is incorporated by reference into the Company’s Registration Statements on Form F-3 (File No. 333-277188, File No. 333-262835, File No. 333-283848, File No. 333-283904,  File No. 333-285030, and File No. 333-287341) and Registration Statements on Form S-8 (File No. 333-269119 and File No. 333-280459), to be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

Cautionary Note Regarding Forward-Looking Statements

 

This Report of Foreign Private Issuer on Form 6-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the terms and potential future issuances of Notes under the SPA and the Company’s intended use of proceeds, and its exploration of strategic opportunities. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs or projections will be achieved, and actual results may differ materially from what is expressed in, or indicated by, the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the SEC, including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F filed on March 31, 2025. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements.

 

2

 

EXHIBIT INDEX

 

Exhibit No.    
4.1   Form of Convertible Promissory Note
10.1   Securities Purchase Agreement, dated June 26, 2025, by and between Jeffs’ Brands Ltd and L.I.A. Pure Capital Ltd.
10.2   Strategic Advisory Agreement, dated June 26, 2025, by and between Jeffs’ Brands Ltd and Aegis Capital Corp
99.1   Press release issued by Jeffs’ Brands Ltd dated June 26, 2025, titled “Jeffs’ Brands Secures $100 million Securities Purchase Agreement to support the Exploration of Strategic Opportunities”

 

3

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Jeffs’ Brands Ltd
     
  By: /s/ Ronen Zalayet
  Name: Ronen Zalayet
  Title: Chief Financial Officer

 

Date: June 26, 2025

 

 

4

 

FAQ

How much capital can Jeffs' Brands (JFBR) raise under the new SPA?

The SPA permits issuance of convertible notes up to $100 million principal in aggregate.

What are the key financial terms of the initial $5 million Note?

Sold for $4.5 million, carries 4 % interest, repayable in ten installments starting 26 Dec 2026, and convertible at the lower of $6.80 or 88 % of 20-day VWAP (floor $1.02856).

When can Jeffs' Brands draw additional tranches?

Beginning 1 December 2025, the company may request tranches up to $2.5 million principal each quarter, priced at 90 % of face value.

What is the maximum ownership the Holder can acquire through conversion?

Conversions are capped so the Holder’s beneficial ownership does not exceed 4.99 % of outstanding ordinary shares.

How will Jeffs' Brands use the proceeds from the Notes?

Management states funds will go toward working capital, general corporate purposes and potential acquisitions.

Is this financing dilutive to existing shareholders?

Yes. The conversion price includes a 12 % discount to market and a 10 % OID, which could increase share count upon conversion.
Jeffs Brands

NASDAQ:JFBRW

JFBRW Rankings

JFBRW Latest News

JFBRW Latest SEC Filings

JFBRW Stock Data

1.72M
Internet Retail
Consumer Cyclical
Link
Israel
Bnei Brak